Elsevier

The Lancet

Volume 321, Issue 8338, 18 June 1983, Pages 1356-1358
The Lancet

CONTROLLED TRIAL OF DEXAMETHASONE THERAPY IN INFANTS WITH BRONCHOPULMONARY DYSPLASIA

https://doi.org/10.1016/S0140-6736(83)92139-6Get rights and content

Abstract

Dexamethasone was compared with placebo in a double-blind, crossover, randomised study of infants with severe bronchopulmonary dysplasia who had required mechanical ventilation for at least four weeks, despite treatment with diuretics, methylxanthines, bronchodilators, fluid restriction, nutritional supplementation, and ligation of the patent ductus arteriosus when indicated. Gestational age ranged from 27 to 33 weeks and birth weight from 800 to 1730 g. Patients received dexamethasone (0·5 mg/kg/day) or normal saline for the first 3 days, then treatment was crossed over for the next 3 days. The study was terminated when sequential analysis showed that all six patients had improved during dexamethasone therapy. Significant improvements were seen in ventilator-determined respiratory rate, peak inspiratory pressure, fractional inspired oxygen concentration, and alveolar arterial oxygen gradients (p<0·05). Although dexamethasone hastened weaning from mechanical ventilation, infection occurred in a substantial proportion of patients.

References (27)

  • Jj Pomerance et al.

    Treatment of neonatal bronchopulmonary dysplasia with steroids

    Ped Res

    (1980)
  • Jb Schick et al.

    Corticosteroid responsiveness in chronic lung disease of prematurity

    Ped Res

    (1981)
  • Jj Pomerance et al.

    Treatment of severe neonatal bronchopulmonary dysplasia with dexamethasone

    Ped Res

    (1982)
  • Cited by (242)

    • Contributions of the NICHD neonatal research network to the diagnosis, prevention, and treatment of bronchopulmonary dysplasia

      2022, Seminars in Perinatology
      Citation Excerpt :

      During the past 35 years, randomized trials and observational studies conducted by the NRN have contributed to our current understanding of the benefits and harms of various corticosteroid medications and dosing strategies used to prevent BPD. Following publication of several small trials conducted in the 1980s showing short-term respiratory benefit with prolonged, high-dose courses of dexamethasone (0.5mg/kg/day starting dose, treatment duration up to 42 days), the NRN conducted two trials in the 1990s that evaluated different dexamethasone treatment regimens.38–42 The first, published in 1998, compared 14-day courses of dexamethasone (0.5mg/kg/day starting dose) initiated at either 2 weeks or 4 weeks of age in 371 ventilator-dependent infants born with birth weights <1500g.41

    • BPD treatments: The never-ending smorgasbord

      2021, Seminars in Fetal and Neonatal Medicine
      Citation Excerpt :

      Because inflammation plays an important part in the pathogenesis of BPD, it was hoped that corticosteroids administered postnatally might reduce lung injury and BPD. Following evidence of effectiveness from several small trials in the 1980's [33,34], postnatal corticosteroids (PCS) became widely used in neonatal units despite the absence of long-term safety data, and animal studies which suggested adverse effects on brain development [35,36]. Subsequent follow-up data confirmed an increased risk of neurological impairment [37,38], and during the 2000's a substantial reduction in PCS use followed.

    • Corticosteroids for Neonatal Hypotension

      2020, Clinics in Perinatology
    View all citing articles on Scopus
    View full text